223 related articles for article (PubMed ID: 22456477)
1. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome.
Barsheshet A; Goldenberg I; O-Uchi J; Moss AJ; Jons C; Shimizu W; Wilde AA; McNitt S; Peterson DR; Zareba W; Robinson JL; Ackerman MJ; Cypress M; Gray DA; Hofman N; Kanters JK; Kaufman ES; Platonov PG; Qi M; Towbin JA; Vincent GM; Lopes CM
Circulation; 2012 Apr; 125(16):1988-96. PubMed ID: 22456477
[TBL] [Abstract][Full Text] [Related]
2. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene.
Moss AJ; Shimizu W; Wilde AA; Towbin JA; Zareba W; Robinson JL; Qi M; Vincent GM; Ackerman MJ; Kaufman ES; Hofman N; Seth R; Kamakura S; Miyamoto Y; Goldenberg I; Andrews ML; McNitt S
Circulation; 2007 May; 115(19):2481-9. PubMed ID: 17470695
[TBL] [Abstract][Full Text] [Related]
3. Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1.
Ruwald MH; Xu Parks X; Moss AJ; Zareba W; Baman J; McNitt S; Kanters JK; Shimizu W; Wilde AA; Jons C; Lopes CM
Heart Rhythm; 2016 Jan; 13(1):122-31. PubMed ID: 26318259
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular genetic risk determinants in adult long QT syndrome type 1 and 2 patients : Koponen et al. Follow-up of adult LQTS patients.
Koponen M; Havulinna AS; Marjamaa A; Tuiskula AM; Salomaa V; Laitinen-Forsblom PJ; Piippo K; Toivonen L; Kontula K; Viitasalo M; Swan H
BMC Med Genet; 2018 Apr; 19(1):56. PubMed ID: 29622001
[TBL] [Abstract][Full Text] [Related]
5. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome.
Costa J; Lopes CM; Barsheshet A; Moss AJ; Migdalovich D; Ouellet G; McNitt S; Polonsky S; Robinson JL; Zareba W; Ackerman MJ; Benhorin J; Kaufman ES; Platonov PG; Shimizu W; Towbin JA; Vincent GM; Wilde AA; Goldenberg I
Heart Rhythm; 2012 Jun; 9(6):892-8. PubMed ID: 22293141
[TBL] [Abstract][Full Text] [Related]
6. Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.
Jons C; Moss AJ; Lopes CM; McNitt S; Zareba W; Goldenberg I; Qi M; Wilde AA; Shimizu W; Kanters JK; Towbin JA; Ackerman MJ; Robinson JL
J Cardiovasc Electrophysiol; 2009 Aug; 20(8):859-65. PubMed ID: 19490272
[TBL] [Abstract][Full Text] [Related]
7. Mutation location effect on severity of phenotype during exercise testing in type 1 long-QT syndrome: impact of transmembrane and C-loop location.
Laksman ZW; Hamilton RM; Chockalingam P; Ballantyne E; Stephenson EA; Gross GJ; Gula LJ; Klein GJ; Wilde AA; Krahn AD
J Cardiovasc Electrophysiol; 2013 Sep; 24(9):1015-20. PubMed ID: 23691991
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological phenotype in the LQTS mutations Y111C and R518X in the KCNQ1 gene.
Diamant UB; Vahedi F; Winbo A; Rydberg A; Stattin EL; Jensen SM; Bergfeldt L
J Appl Physiol (1985); 2013 Nov; 115(10):1423-32. PubMed ID: 24052033
[TBL] [Abstract][Full Text] [Related]
9. Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients.
Morgat C; Fressart V; Porretta AP; Neyroud N; Messali A; Temmar Y; Algalarrondo V; Surget E; Bloch A; Leenhardt A; Denjoy I; Extramiana F
Europace; 2024 Jun; 26(6):. PubMed ID: 38825991
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of 316 molecularly defined pediatric long-QT syndrome patients: clinical course, treatments, and side effects.
Koponen M; Marjamaa A; Hiippala A; Happonen JM; Havulinna AS; Salomaa V; Lahtinen AM; Hintsa T; Viitasalo M; Toivonen L; Kontula K; Swan H
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):815-23. PubMed ID: 26063740
[TBL] [Abstract][Full Text] [Related]
11. Low incidence of sudden cardiac death in a Swedish Y111C type 1 long-QT syndrome population.
Winbo A; Diamant UB; Stattin EL; Jensen SM; Rydberg A
Circ Cardiovasc Genet; 2009 Dec; 2(6):558-64. PubMed ID: 20031635
[TBL] [Abstract][Full Text] [Related]
12. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management.
Goldenberg I; Bradley J; Moss A; McNitt S; Polonsky S; Robinson JL; Andrews M; Zareba W;
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):893-901. PubMed ID: 20233272
[TBL] [Abstract][Full Text] [Related]
13. In silico cardiac risk assessment in patients with long QT syndrome: type 1: clinical predictability of cardiac models.
Hoefen R; Reumann M; Goldenberg I; Moss AJ; O-Uchi J; Gu Y; McNitt S; Zareba W; Jons C; Kanters JK; Platonov PG; Shimizu W; Wilde AA; Rice JJ; Lopes CM
J Am Coll Cardiol; 2012 Nov; 60(21):2182-91. PubMed ID: 23153844
[TBL] [Abstract][Full Text] [Related]
14. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation?
Heradien MJ; Goosen A; Crotti L; Durrheim G; Corfield V; Brink PA; Schwartz PJ
J Am Coll Cardiol; 2006 Oct; 48(7):1410-5. PubMed ID: 17010804
[TBL] [Abstract][Full Text] [Related]
15. Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
Moretti A; Bellin M; Welling A; Jung CB; Lam JT; Bott-Flügel L; Dorn T; Goedel A; Höhnke C; Hofmann F; Seyfarth M; Sinnecker D; Schömig A; Laugwitz KL
N Engl J Med; 2010 Oct; 363(15):1397-409. PubMed ID: 20660394
[TBL] [Abstract][Full Text] [Related]
16. Effective long-term control of cardiac events with beta-blockers in a family with a common LQT1 mutation.
Wedekind H; Schwarz M; Hauenschild S; Djonlagic H; Haverkamp W; Breithardt G; Wülfing T; Pongs O; Isbrandt D; Schulze-Bahr E
Clin Genet; 2004 Mar; 65(3):233-41. PubMed ID: 14756674
[TBL] [Abstract][Full Text] [Related]
17. PKA and PKC partially rescue long QT type 1 phenotype by restoring channel-PIP2 interactions.
Matavel A; Medei E; Lopes CM
Channels (Austin); 2010; 4(1):3-11. PubMed ID: 19934648
[TBL] [Abstract][Full Text] [Related]
18. Genotype-based clinical manifestation and treatment of Chinese long QT syndrome patients with KCNQ1 mutations - R380S and W305L.
Zhou H; Lai W; Zhu W; Xie J; Liu X; Shen Y; Yuan P; Liu Y; Cao Q; He W; Hong K
Cardiol Young; 2016 Apr; 26(4):754-63. PubMed ID: 26344792
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures".
Vincent GM; Schwartz PJ; Denjoy I; Swan H; Bithell C; Spazzolini C; Crotti L; Piippo K; Lupoglazoff JM; Villain E; Priori SG; Napolitano C; Zhang L
Circulation; 2009 Jan; 119(2):215-21. PubMed ID: 19118258
[TBL] [Abstract][Full Text] [Related]
20. Use of mutant-specific ion channel characteristics for risk stratification of long QT syndrome patients.
Jons C; O-Uchi J; Moss AJ; Reumann M; Rice JJ; Goldenberg I; Zareba W; Wilde AA; Shimizu W; Kanters JK; McNitt S; Hofman N; Robinson JL; Lopes CM
Sci Transl Med; 2011 Mar; 3(76):76ra28. PubMed ID: 21451124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
